|

Hepatocellular Carcinoma Identification Using Delta-HLD

RECRUITINGSponsored by Epiliquid Holding, Inc
Actively Recruiting
SponsorEpiliquid Holding, Inc
Started2023-05-18
Est. completion2026-08-12
Eligibility
Age18 Years – 75 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07148310

Summary

HIDE (Hepatocellular Carcinoma Identification via Delta-HLD) is a proof-of-concept case-control study designed to evaluate the performance of delta-HLD, Epiliquid's proprietary liquid biopsy technology, in detecting hepatocellular carcinoma (HCC). The study includes both plasma and tissue samples to assess biomarker concordance and evaluate diagnostic sensitivity and specificity using tumor-specific methylation markers detected by PCR.

Eligibility

Age: 18 Years – 75 YearsHealthy volunteers accepted
Inclusion Criteria:

* Histologically confirmed HCC (cases) or clinically confirmed liver cirrhosis without HCC (controls)
* Willing and able to provide informed consent
* Available paired plasma and liver tissue sample

Exclusion Criteria:

* Other active cancers
* Prior liver transplantation
* Known hereditary cancer syndromes
* Recent chemotherapy or antiviral treatment (\<3 months)

Conditions4

CancerHepato Cellular Carcinoma (HCC)Liver CancerLiver Disease

Browse More Trials

Cancer trialsLiver Disease trialsLiver Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.